Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Phase 2 trial registration with no results posted; study is actively recruiting and designed to assess efficacy and safety of tirzepatide in binge-eating disorder.
FDA supplemental approval of labeling change for Vyvanse (lisdexamfetamine dimesylate); this is a regulatory action, not a clinical trial, and does not report efficacy or comparative benefit data.